… did not seem to restore susceptibility in vitro for most of the imipenem-resistant isolates.
Rates of drug-related adverse events were similar among all treatment groups at 13.7%, 13.8%, …

… Imipenem-relebactam inhibited all isolates of the 10 most commonly collected … for
imipenem (1 μg/ml) with three exceptions: K. pneumoniae (99.4% susceptible to imipenem-relebactam)…

… Relebactam restores activity to imipenem in most isolates of … Imipenem/relebactam is also
active against isolates of P. … in a collection of clinical isolates of Enterobacterales and P. …

… of this study, imipenem breakpoints were used to interpret susceptibility to imipenem plus
relebactam. … Among the 144 isolates that were not susceptible to imipenem, the addition of …

… 8.1 clinical breakpoints (www.eucast.org). In this work, we used broth microdilution to
determine the MICs of imipenem and imipenem plus relebactam 4 μg/ml for the 1,445 isolates. For …

… relebactam can overcome imipenem non-susceptibility in clinical isolates of this pathogen. …
We also compared the in vitro activities of relebactam plus imipenem versus imipenem alone …

… isolates. In this study, the in vitro antibacterial activity of IMR against clinical isolates …
tests using clinical isolates collected prospectively from medical institutions across Japan in …

… Prescreening for gram-negative isolates nonsusceptible to imipenem but susceptible to
both imipenem/relebactam and colistin. a From specimen types of interest, including blood, …

… The SMART program was initiated in 2002 and includes collection and assessment of clinical
isolates by hospital laboratories for monitoring antibacterial susceptibility profiles of gram-…

… aeruginosa isolates. Consistent with most new β-lactams except cefiderocol, I/R does not …
Imipenem/cilastatin/relebactam is currently approved by the Food and Drug Administration (…